• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Do Contraceptives Decrease Risk for All Ovarian Cancers?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Older studies using older hormonal contraceptive formulations protect against ovarian cancer
  • Limited data on newer formulations
  • Iverson et al. (BMJ, 2018) assessed whether contemporary combined hormonal contraceptives are associated with overall and specific types of ovarian cancer

METHODS:

  • Prospective, nationwide cohort study (1995-2014)
  • Participants
    • Women age 15-45 years
    • Follow-up until whichever came first: First diagnosis of ovarian cancer death, emigration, age 50 years, or end of follow-up (December 31, 2014)
  • Women’s exposure to contraceptives were categorized as
    • Never users (reference): No record of being dispensed hormonal contraception
    • Current users
    • Recent users: ≤1 year after stopping use
    • Former users: >1 year after stopping use
  • Contraceptives were categorized by
    • Progestogen type in combined preparations
    • All progestogen-only products (including non-oral preparations)
  • Separate analyses examined women followed up to their first contraception type switch and those with full contraceptive histories
  • Primary outcome
    • Relative risk (RR) of ovarian cancer

RESULTS:

  • 1,879,227 women were included
  • During 21.4 million person years, 1,249 incident ovarian cancers occurred
    • Among ever users of hormonal contraception, 478 ovarian cancers were recorded over 13,344,531 person years
    • Never users had 771 ovarian cancers during 8,150,250 person years
  • Compared with never users, ovarian cancer risk was reduced among those who had used hormonal contraceptives
    • Current or recent use: RR 0.58 (95% CI, 0.49 to 0.68)
    • Former use: RR 0.77 (95% CI, 0.66 to 0.91)
  • Relative risks among current or recent users decreased with increasing duration (P<0.001)
    • ≤1 year use: RR 0.82 (95% CI, 0.59 to 1.12)
    • >10 years’ use: RR 0.26 (95% CI, 0.16 to 0.43)
  • Little evidence of major differences based on
    • Tumor type
    • Progestogen content of combined OCPs
  • Progestogen-only products did not alter ovarian cancer risk

CONCLUSION:

  • Contemporary combined hormonal contraceptives, like previous formulations, are associated with a reduction in ovarian cancer risk
  • No effect seen in progesterone-only contraceptives
  • Duration of use increased the protective effect
  • The authors state

It has been suggested that recent downward trends in ovarian cancer mortality rates in North America and Europe can be partly attributed to the use of combined oral contraceptives. We found a population prevented fraction of 21% with use of hormonal contraception, which supports the notion that these ovarian cancer mortality benefits are likely to continue.

Learn More – Primary Sources:

Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study

image_pdfFavoriteLoadingFavorite

< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

USPSTF Releases Final Recommendation On Ovarian Cancer Screening
ACOG Practice Advisory: Counseling Patients About Breast Cancer Risk and Hormonal Contraception
Practical info for your gynecology practice
Hormonal Contraception Benefits – Beyond Pregnancy Prevention

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site